Study identifier:D7550C00003
ClinicalTrials.gov identifier:NCT03317002
EudraCT identifier:N/A
CTIS identifier:N/A
A 12-week, randomized, single-blind, placebo-controlled, multi-centre, parallel group, phase IIa study to evaluate efficacy, safety and tolerability of oral AZD5718 after 4 and 12-weeks of treatment in patients with coronary artery disease (CAD)
Coronary artery disease
Phase 2
No
AZD5718, Placebo
All
129
Interventional
18 Years - 75 Years
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Treatment
Verified 01 Jun 2021 by AstraZeneca
AstraZeneca
-
This is a randomized, single-blind, placebo-controlled, parallel-group, multicentre study in patients with CAD. The study will be conducted at approximately 10 centres in 3 countries. Approximately 138 CAD patients will be randomized to AZD5718 or placebo (treatment duration 12 weeks).
This is a randomized, single-blind, placebo-controlled, parallel-group, multicentre study in patients with CAD. The study will be conducted at approximately 10 centres in 3 countries (Denmark, Finland and Sweden). Patients suitable for the study will be identified and screened for eligibility after being hospitalized for Acute Coronary Syndrome (ACS) (Visit 1) comprising ST Elevation Myocardial Infarction (STEMI) or Non-ST Elevation Myocardial Infarction (non-STEMI). At Visit 1, after signing informed consent, study measurements will take place at days 1, 2, 3 and 5 post ACS, where feasible. It is planned that approximately 138 CAD patients will be randomized to ensure at least 66 evaluable patients receiving AZD5718 Dose B or placebo are included with 12 weeks treatment. For supporting dose selection in future studies, a treatment arm with 28 randomized patients receiving AZD5718 Dose A is included in the study. The study was originally designed to be a 4-week study and was amended to be a 12-week study. Therefore, the total number of patients is greater than required for a 12 weeks study (about 100), since some patients will only have 4 weeks of treatment. An evaluable patient is defined as a patient with a valid Coronary Flow Velocity Reserve (CFVR) measurement at Visit 2 and one post baseline visit as judged by the CFVR Core lab. On Day 1 (Visit 2), 7 to 28 days after the ACS event, patients willing to participate in the study will complete the screening procedure and, if eligible, be randomized. Treatment duration will be 12 weeks. During the treatment phase, patients will come in to the clinic for study measurements at 2 weeks (visit 3), 4 weeks (visit 4), 8 weeks (visit 4b) and 12 weeks (visit 4c). A follow-up visit (Visit 5) will be performed at 4 weeks (±4 days) after last dose in order to ensure safety and well-being of the patients
Location
Location
Frederiksberg, Denmark, 2000
Location
Aarhus, Denmark, 8200
Location
Odense C, Denmark, 5000
Location
Turku, Finland, 20520
Location
Stockholm, Sweden, 171 76
Location
GÖTEBORG, Sweden, 413 45
Location
Lund, Sweden, 222 42
Location
Uppsala, Sweden, 75185
Arms | Assigned Interventions |
---|---|
Experimental: AZD5718 Dose A AZD5718 Dose A once daily | Drug: AZD5718 Oral dose of AZD5718 (tablet) |
Experimental: AZD5718 Dose B AZD5718 Dose B once daily | Drug: AZD5718 Oral dose of AZD5718 (tablet) |
Placebo Comparator: Placebo Matching placebo once daily | Drug: Placebo Matching placebo (tablet) |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.